The deal gives Sanofi access to Seawolf’s DNA-based medicine platform as it expands its pipeline of potential treatments for conditions with unmet medical needs.

USA— US drugmaker Seawolf Therapeutics and French pharmaceutical company Sanofi have signed a multi-target research and exclusive licensing agreement worth up to US$1.2 billion to develop gene therapies for bleeding disorders and other undisclosed conditions.
Under the agreement, Seawolf is eligible to receive payments tied to research, development and commercial milestones, as well as tiered royalties on future sales of therapies developed through the collaboration.
The deal gives Sanofi access to Seawolf’s DNA-based medicine platform as it expands its pipeline of potential treatments for conditions with unmet medical needs.
The partnership coincides with Seawolf’s emergence from stealth mode following US$100m in financing to advance its therapeutic pipeline.
The funding comprises seed financing led by founding investor Versant Ventures and a Series A round backed by MPM BioImpact, Novartis Venture Fund and Versant Ventures.
Other investors include Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly and Company, Pathway to Cures, the philanthropic venture arm of the National Bleeding Disorders Foundation, and Sixty Degree Capital.
Seawolf president and CEO Elizabeth Alcamo said the company aims to advance patient care through lipid nanoparticle (LNP)-based DNA medicines.
She identified the Sanofi collaboration and investor backing as important to the company’s growth plans, which also include advancing an internal programme targeting metabolic diseases.
Advancing DNA-based medicine
Seawolf will use the financing to advance candidates developed through its Targeted RNA-Induced DNA Expression via Nuclear Translocation (TRIDENT) platform.
The technology uses LNPs to deliver DNA carrying instructions for producing therapeutic proteins directly into cell nuclei.
An auxiliary factor supports the delivery process, while the platform uses immune-quiet DNA designed to reduce unwanted immune responses.
By targeting the cell nucleus, the approach aims to achieve sustained production of therapeutic proteins, potentially overcoming the short-lived effects associated with conventional RNA-based treatments.
The technology also offers a different delivery model from viral vectors, as its nanoparticle system is designed to support repeated administration, allowing treatment doses to be adjusted or supplemented over time.
Seawolf has demonstrated proof of concept in preclinical studies involving mouse and non-human primate models of metabolic and rare diseases.
The company is also advancing an internal lead candidate for metabolic diseases alongside its work with Sanofi.
The agreement reflects growing pharmaceutical industry interest in non-viral delivery technologies that could expand the range of genetic medicines available for chronic and rare conditions.
For Sanofi, the collaboration provides access to an alternative DNA delivery platform, while Seawolf gains a pharmaceutical development partner and milestone-based funding to support its research and development activities.
Be the first to leave a comment